Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New pill RAP-219 tested for stubborn seizures

NCT ID NCT06377930

Disease control Sponsor: Rapport Therapeutics Inc. Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tested an investigational drug called RAP-219 in 30 adults with refractory focal epilepsy—seizures that don't respond well to current treatments. Participants took RAP-219 tablets to see if it safely reduces seizure frequency. The trial is now complete, and results will help determine if further testing is warranted.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
RAP-219 oral tablet
What this could lead to
If successful, RAP-219 could offer a new treatment option for people with hard-to-control focal epilepsy, potentially reducing seizure frequency.
What could go wrong
This is a small, early-phase (Phase 2A) open-label study with no placebo group, so results may not confirm effectiveness. Side effects and lack of long-term data are also concerns.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 2

Tests whether the treatment actually works, and watches for side effects, in a larger group.

Participants

30 people

The number who actually took part.

Started

Oct 2024

Finished

Sep 2025

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 65 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Medically refractory focal epilepsy with an implanted responsive neurostimulator device placed correctly in a seizure onset zone that meet several device-related criteria and demonstrated history of compliance with interrogation of the RNS device and upload of data * If currently treated with antiseizure medications, up to a maximum of 4 concomitant mediations are allowed * At least 1 clinical seizure during the 8-week retrospective eligibility period * Participants in otherwise good health as determined by the investigator * Willing and able to adhere to all aspects of the protocol * A demonstrated history of compliance with interrogation of the RNS device and upload of data before screening Exclusion Criteria: * Participants with generalized onset seizures in the past 10 years * History of status epilepticus while on antiseizure medications within 2 years of screening * Individuals of reproductive potential who do not agree to simultaneously use two effective birth-control methods * Participants who have had epilepsy surgery within the last 12 months before screening

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Focal-onset seizures are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

epilepsy focal epilepsy visual epilepsy

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Focal-onset seizures

Contacts and locations

Locations

  • Baylor College of Medicine

    Houston, Texas, 770300, United States

  • Cleveland Clinic Foundation

    Cleveland, Ohio, 44195, United States

  • Consultants in Epilepsy and Neurology, PLLC

    Boise, Idaho, 83702, United States

  • IU Health Neuroscience Center, Goodman Hall

    Indianapolis, Indiana, 46202, United States

  • Mayo Clinic

    Rochester, Minnesota, 55905, United States

  • NYU Langone Comprehensive Epilepsy Center

    New York, New York, 10016, United States

  • The University of Kansas Medical Center Epilepsy Clinic

    Kansas City, Kansas, 66160, United States

  • Thomas Jefferson University

    Philadelphia, Pennsylvania, 19107, United States

  • University of Pennsylvania - Department of Neurology

    Philadelphia, Pennsylvania, 19104, United States

  • University of Texas Health Science Center, Houston

    Houston, Texas, 77030, United States

  • Vanderbilt University Medical Center

    Nashville, Tennessee, 37232, United States

  • Yale University

    New Haven, Connecticut, 06519, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.